\begin{longtable}[l]{rr@{}l@{ }} \caption{Effects of 771 MeSH terms} \\ 
Biomarkers & -0.831 (0.106) & $^{***}$\\
Sex Characteristics & -0.805 (0.220) & $^{***}$\\
Vitamin D/blood & -0.688 (0.267) & $^{*}$\\
Geriatric Assessment & -0.676 (0.172) & $^{***}$\\
Enzyme-Linked Immunosorbent Assay & -0.669 (0.186) & $^{***}$\\
Heart Arrest/mortality & -0.663 (0.267) & $^{*}$\\
Ventricular Dysfunction, Left/diagnostic imaging & -0.650 (0.261) & $^{*}$\\
Glasgow Coma Scale & -0.595 (0.168) & $^{***}$\\
Respiration, Artificial/statistics \& numerical data & -0.570 (0.207) & $^{**}$\\
Renal Dialysis/mortality & -0.554 (0.271) & $^{*}$\\
Immunohistochemistry & -0.523 (0.201) & $^{**}$\\
Predictive Value of Tests & -0.521 (0.050) & $^{***}$\\
Stroke/diagnostic imaging & -0.512 (0.197) & $^{**}$\\
Athletes & -0.510 (0.201) & $^{*}$\\
Renal Insufficiency, Chronic/blood & -0.508 (0.227) & $^{*}$\\
Reference Values & -0.507 (0.141) & $^{***}$\\
ROC Curve & -0.502 (0.082) & $^{***}$\\
Kidney Failure, Chronic/epidemiology & -0.502 (0.236) & $^{*}$\\
Risk & -0.498 (0.130) & $^{***}$\\
Carotid Intima-Media Thickness & -0.495 (0.232) & $^{*}$\\
Percutaneous Coronary Intervention/adverse effects & -0.481 (0.136) & $^{***}$\\
Tomography, Optical Coherence/methods & -0.473 (0.111) & $^{***}$\\
Prognosis & -0.456 (0.038) & $^{***}$\\
Organ Size & -0.456 (0.183) & $^{*}$\\
Survivors & -0.454 (0.204) & $^{*}$\\
Postoperative Complications/blood & -0.451 (0.238) & $^{}$\\
Anthropometry & -0.447 (0.201) & $^{*}$\\
Polymorphism, Single Nucleotide & -0.446 (0.158) & $^{**}$\\
Magnetic Resonance Imaging/methods & -0.445 (0.120) & $^{***}$\\
Stroke/diagnosis & -0.444 (0.144) & $^{**}$\\
Kidney Failure, Chronic/mortality & -0.441 (0.223) & $^{*}$\\
Choroid/pathology & -0.423 (0.218) & $^{}$\\
Biomarkers/blood & -0.421 (0.057) & $^{***}$\\
Lung/diagnostic imaging & -0.420 (0.161) & $^{**}$\\
Neuropsychological Tests & -0.411 (0.135) & $^{**}$\\
Lactic Acid/blood & -0.410 (0.227) & $^{}$\\
Atrial Fibrillation/therapy & -0.408 (0.212) & $^{}$\\
Tomography, Optical Coherence & -0.402 (0.104) & $^{***}$\\
Aortic Valve/surgery & -0.399 (0.197) & $^{*}$\\
Up-Regulation & -0.393 (0.195) & $^{*}$\\
Cardiovascular Diseases/diagnosis & -0.391 (0.168) & $^{*}$\\
Stroke Volume & -0.390 (0.132) & $^{**}$\\
Prevalence & -0.386 (0.046) & $^{***}$\\
Pain, Postoperative/etiology & -0.383 (0.175) & $^{*}$\\
Hand Strength & -0.382 (0.177) & $^{*}$\\
Blood Glucose & -0.381 (0.148) & $^{**}$\\
Cesarean Section/statistics \& numerical data & -0.381 (0.188) & $^{*}$\\
Coronary Artery Bypass/adverse effects & -0.378 (0.196) & $^{}$\\
Self Report & -0.377 (0.104) & $^{***}$\\
Aortic Aneurysm, Abdominal/surgery & -0.376 (0.210) & $^{}$\\
Diabetes Mellitus, Type 1/epidemiology & -0.374 (0.211) & $^{}$\\
Patient Readmission & -0.373 (0.147) & $^{*}$\\
Cardiovascular Diseases/physiopathology & -0.373 (0.240) & $^{}$\\
Preoperative Period & -0.371 (0.146) & $^{*}$\\
Social Class & -0.369 (0.183) & $^{*}$\\
Asthma/epidemiology & -0.363 (0.192) & $^{}$\\
Plaque, Atherosclerotic & -0.363 (0.267) & $^{}$\\
Biomarkers/metabolism & -0.361 (0.133) & $^{**}$\\
Pneumonia, Viral/epidemiology & -0.357 (0.450) & $^{}$\\
Heart Disease Risk Factors & -0.356 (0.197) & $^{}$\\
COVID-19/mortality & -0.354 (0.166) & $^{*}$\\
Ultrasonography, Prenatal & -0.352 (0.179) & $^{*}$\\
Diabetes Mellitus/blood & -0.349 (0.245) & $^{}$\\
Patient Readmission/statistics \& numerical data & -0.347 (0.147) & $^{*}$\\
Risk Factors & -0.342 (0.027) & $^{***}$\\
Shock, Septic/mortality & -0.341 (0.239) & $^{}$\\
Cardiopulmonary Resuscitation & -0.337 (0.182) & $^{}$\\
Delirium/diagnosis & -0.333 (0.254) & $^{}$\\
Inflammation & -0.331 (0.184) & $^{}$\\
Cross-Sectional Studies & -0.331 (0.030) & $^{***}$\\
Medication Adherence/statistics \& numerical data & -0.326 (0.153) & $^{*}$\\
Glomerular Filtration Rate & -0.325 (0.112) & $^{**}$\\
Postoperative Complications/physiopathology & -0.325 (0.184) & $^{}$\\
Pulmonary Veins/surgery & -0.324 (0.215) & $^{}$\\
Viral Load & -0.321 (0.147) & $^{*}$\\
Weight Gain & -0.320 (0.182) & $^{}$\\
Neoplasms/epidemiology & -0.320 (0.163) & $^{}$\\
Feeding Behavior & -0.318 (0.179) & $^{}$\\
Heart Valve Prosthesis Implantation/adverse effects & -0.318 (0.226) & $^{}$\\
Spirometry & -0.317 (0.210) & $^{}$\\
Depression/epidemiology & -0.310 (0.133) & $^{*}$\\
Echocardiography/methods & -0.310 (0.186) & $^{}$\\
Age of Onset & -0.304 (0.161) & $^{}$\\
Brain Ischemia/epidemiology & -0.303 (0.253) & $^{}$\\
Heart Failure/blood & -0.298 (0.238) & $^{}$\\
Neoplasm Grading & -0.297 (0.185) & $^{}$\\
White People & -0.296 (0.198) & $^{}$\\
Postoperative Complications/diagnosis & -0.296 (0.132) & $^{*}$\\
Obesity/epidemiology & -0.295 (0.136) & $^{*}$\\
Electroencephalography & -0.294 (0.175) & $^{}$\\
Medicare & -0.293 (0.158) & $^{}$\\
Geriatric Assessment/methods & -0.292 (0.186) & $^{}$\\
Incidence & -0.290 (0.040) & $^{***}$\\
Hypertension/complications & -0.284 (0.148) & $^{}$\\
Glucose Tolerance Test & -0.284 (0.213) & $^{}$\\
Hospital Mortality/trends & -0.283 (0.136) & $^{*}$\\
ST Elevation Myocardial Infarction/diagnosis & -0.280 (0.218) & $^{}$\\
Adiposity & -0.278 (0.222) & $^{}$\\
Inflammation/blood & -0.278 (0.207) & $^{}$\\
Percutaneous Coronary Intervention & -0.277 (0.134) & $^{*}$\\
Patient Discharge/statistics \& numerical data & -0.277 (0.177) & $^{}$\\
Pregnancy Outcome/epidemiology & -0.276 (0.167) & $^{}$\\
C-Reactive Protein/metabolism & -0.274 (0.141) & $^{}$\\
Hospital Mortality & -0.274 (0.059) & $^{***}$\\
Aortic Valve Stenosis/diagnostic imaging & -0.273 (0.268) & $^{}$\\
Medication Adherence & -0.272 (0.121) & $^{*}$\\
Angiotensin-Converting Enzyme Inhibitors/therapeutic use & -0.269 (0.200) & $^{}$\\
Emergency Medical Services & -0.268 (0.130) & $^{*}$\\
Stroke/complications & -0.266 (0.140) & $^{}$\\
Pulmonary Disease, Chronic Obstructive/epidemiology & -0.266 (0.178) & $^{}$\\
Myocardial Infarction/complications & -0.265 (0.211) & $^{}$\\
Heart Rate/physiology & -0.262 (0.142) & $^{}$\\
Myocardial Infarction/mortality & -0.259 (0.154) & $^{}$\\
Case-Control Studies & -0.258 (0.044) & $^{***}$\\
Vascular Stiffness & -0.257 (0.270) & $^{}$\\
Ultrasonography/methods & -0.256 (0.145) & $^{}$\\
Platelet Aggregation Inhibitors/administration \& dosage & -0.255 (0.217) & $^{}$\\
Analgesics, Opioid/adverse effects & -0.249 (0.186) & $^{}$\\
Diabetes Mellitus, Type 2/complications & -0.247 (0.097) & $^{*}$\\
Heart Failure/physiopathology & -0.247 (0.146) & $^{}$\\
Leukocyte Count & -0.245 (0.183) & $^{}$\\
Cardiac Surgical Procedures/adverse effects & -0.245 (0.125) & $^{*}$\\
Inpatients & -0.245 (0.114) & $^{*}$\\
Heart Defects, Congenital/surgery & -0.244 (0.183) & $^{}$\\
COVID-19/complications & -0.244 (0.107) & $^{*}$\\
Lymphocyte Count & -0.242 (0.232) & $^{}$\\
Spectroscopy, Near-Infrared & -0.240 (0.205) & $^{}$\\
Practice Patterns, Physicians' & -0.240 (0.150) & $^{}$\\
Hospitalization & -0.239 (0.058) & $^{***}$\\
Diabetes Mellitus, Type 2/epidemiology & -0.237 (0.112) & $^{*}$\\
Critical Care & -0.236 (0.113) & $^{*}$\\
Emergency Medical Services/methods & -0.236 (0.180) & $^{}$\\
Anticoagulants/adverse effects & -0.236 (0.140) & $^{}$\\
Infant, Very Low Birth Weight & -0.234 (0.194) & $^{}$\\
Independent Living & -0.233 (0.195) & $^{}$\\
Sepsis/diagnosis & -0.231 (0.175) & $^{}$\\
Health Status & -0.231 (0.099) & $^{*}$\\
Proportional Hazards Models & -0.230 (0.065) & $^{***}$\\
Sedentary Behavior & -0.228 (0.180) & $^{}$\\
Cognition & -0.227 (0.122) & $^{}$\\
Myocardial Infarction/etiology & -0.227 (0.187) & $^{}$\\
Premature Birth/epidemiology & -0.227 (0.187) & $^{}$\\
Angiogenesis Inhibitors/therapeutic use & -0.227 (0.201) & $^{}$\\
Tomography, X-Ray Computed & -0.225 (0.082) & $^{**}$\\
Diabetes Mellitus & -0.225 (0.166) & $^{}$\\
Stroke Volume/physiology & -0.223 (0.176) & $^{}$\\
Nutrition Assessment & -0.222 (0.177) & $^{}$\\
Practice Patterns, Physicians'/statistics \& numerical data & -0.220 (0.143) & $^{}$\\
Ultrasonography & -0.219 (0.081) & $^{**}$\\
Glomerular Filtration Rate/physiology & -0.216 (0.218) & $^{}$\\
HIV Infections/complications & -0.215 (0.127) & $^{}$\\
Renal Dialysis & -0.211 (0.112) & $^{}$\\
Absorptiometry, Photon & -0.210 (0.194) & $^{}$\\
Magnetic Resonance Imaging & -0.210 (0.082) & $^{*}$\\
Anti-Retroviral Agents/therapeutic use & -0.209 (0.210) & $^{}$\\
Sepsis/blood & -0.209 (0.215) & $^{}$\\
Gestational Age & -0.206 (0.087) & $^{*}$\\
Stroke/etiology & -0.206 (0.132) & $^{}$\\
Morbidity & -0.205 (0.174) & $^{}$\\
Respiration, Artificial & -0.205 (0.100) & $^{*}$\\
Coronary Artery Disease/epidemiology & -0.204 (0.178) & $^{}$\\
Biomarkers/urine & -0.204 (0.189) & $^{}$\\
C-Reactive Protein/analysis & -0.203 (0.142) & $^{}$\\
Intensive Care Units & -0.202 (0.064) & $^{**}$\\
Monitoring, Physiologic/methods & -0.197 (0.170) & $^{}$\\
Heart Valve Prosthesis Implantation/mortality & -0.190 (0.260) & $^{}$\\
Fundus Oculi & -0.190 (0.187) & $^{}$\\
Logistic Models & -0.189 (0.055) & $^{***}$\\
Anticoagulants/therapeutic use & -0.189 (0.118) & $^{}$\\
Sex Factors & -0.189 (0.066) & $^{**}$\\
Cholesterol, HDL/blood & -0.188 (0.223) & $^{}$\\
Reoperation/statistics \& numerical data & -0.186 (0.178) & $^{}$\\
Biomechanical Phenomena & -0.186 (0.156) & $^{}$\\
Sex Distribution & -0.186 (0.163) & $^{}$\\
Blood Pressure & -0.186 (0.101) & $^{}$\\
Phenotype & -0.183 (0.118) & $^{}$\\
Electric Impedance & -0.183 (0.192) & $^{}$\\
Peripheral Arterial Disease/diagnosis & -0.179 (0.210) & $^{}$\\
Postoperative Complications/epidemiology & -0.178 (0.068) & $^{**}$\\
Coronary Artery Disease/physiopathology & -0.178 (0.186) & $^{}$\\
Biopsy & -0.178 (0.114) & $^{}$\\
Hypertension/diagnosis & -0.177 (0.183) & $^{}$\\
Postpartum Period & -0.176 (0.179) & $^{}$\\
Peptide Fragments/blood & -0.176 (0.247) & $^{}$\\
Biomarkers/analysis & -0.176 (0.145) & $^{}$\\
Out-of-Hospital Cardiac Arrest/therapy & -0.175 (0.162) & $^{}$\\
Diabetes Mellitus, Type 1/blood & -0.174 (0.201) & $^{}$\\
Laparoscopy/adverse effects & -0.173 (0.168) & $^{}$\\
Emergency Service, Hospital/statistics \& numerical data & -0.173 (0.097) & $^{}$\\
COVID-19/diagnosis & -0.172 (0.143) & $^{}$\\
Cohort Studies & -0.171 (0.029) & $^{***}$\\
Fluorescein Angiography & -0.171 (0.163) & $^{}$\\
Blood Glucose/analysis & -0.169 (0.130) & $^{}$\\
Electrocardiography & -0.169 (0.104) & $^{}$\\
Computed Tomography Angiography & -0.168 (0.167) & $^{}$\\
Kidney Failure, Chronic/complications & -0.168 (0.193) & $^{}$\\
Mortality/trends & -0.168 (0.170) & $^{}$\\
Myocardial Infarction/epidemiology & -0.167 (0.152) & $^{}$\\
Disease Progression & -0.167 (0.056) & $^{**}$\\
Child Development & -0.165 (0.195) & $^{}$\\
Pulmonary Disease, Chronic Obstructive/physiopathology & -0.165 (0.164) & $^{}$\\
ST Elevation Myocardial Infarction/mortality & -0.163 (0.246) & $^{}$\\
Fluorescein Angiography/methods & -0.162 (0.203) & $^{}$\\
Microbial Sensitivity Tests & -0.160 (0.155) & $^{}$\\
Macula Lutea/pathology & -0.160 (0.208) & $^{}$\\
SARS-CoV-2 & -0.158 (0.070) & $^{*}$\\
Longitudinal Studies & -0.157 (0.043) & $^{***}$\\
Creatinine/blood & -0.155 (0.147) & $^{}$\\
Postmenopause & -0.155 (0.201) & $^{}$\\
Cardiac Surgical Procedures & -0.154 (0.156) & $^{}$\\
Patient Acceptance of Health Care & -0.149 (0.161) & $^{}$\\
Polypharmacy & -0.148 (0.192) & $^{}$\\
Frail Elderly & -0.147 (0.193) & $^{}$\\
Cardiopulmonary Resuscitation/methods & -0.145 (0.182) & $^{}$\\
Atrial Fibrillation/epidemiology & -0.145 (0.145) & $^{}$\\
Drug-Eluting Stents & -0.143 (0.181) & $^{}$\\
Patient Reported Outcome Measures & -0.141 (0.108) & $^{}$\\
Registries & -0.139 (0.046) & $^{**}$\\
Acute Kidney Injury/mortality & -0.139 (0.203) & $^{}$\\
Databases, Factual & -0.138 (0.071) & $^{}$\\
Depression/etiology & -0.138 (0.196) & $^{}$\\
Mortality & -0.137 (0.144) & $^{}$\\
Intensive Care Units, Pediatric & -0.136 (0.153) & $^{}$\\
Atrial Fibrillation/mortality & -0.135 (0.201) & $^{}$\\
Acute Kidney Injury/diagnosis & -0.135 (0.165) & $^{}$\\
Kidney Failure, Chronic/diagnosis & -0.133 (0.230) & $^{}$\\
Transcatheter Aortic Valve Replacement/adverse effects & -0.132 (0.218) & $^{}$\\
Diabetes Mellitus, Type 1/complications & -0.132 (0.178) & $^{}$\\
Sepsis/mortality & -0.131 (0.173) & $^{}$\\
Oxygen & -0.131 (0.161) & $^{}$\\
Health Care Costs & -0.128 (0.137) & $^{}$\\
Pulmonary Disease, Chronic Obstructive/complications & -0.128 (0.187) & $^{}$\\
Aortic Valve Stenosis/physiopathology & -0.128 (0.313) & $^{}$\\
Heart Failure/diagnosis & -0.126 (0.142) & $^{}$\\
Multivariate Analysis & -0.126 (0.061) & $^{*}$\\
Insulin Resistance & -0.126 (0.153) & $^{}$\\
Critical Illness & -0.125 (0.084) & $^{}$\\
Depression/psychology & -0.125 (0.155) & $^{}$\\
Perception & -0.124 (0.174) & $^{}$\\
Disability Evaluation & -0.122 (0.098) & $^{}$\\
Antirheumatic Agents/therapeutic use & -0.121 (0.140) & $^{}$\\
Platelet Aggregation Inhibitors/therapeutic use & -0.121 (0.148) & $^{}$\\
Patient Admission & -0.121 (0.151) & $^{}$\\
Syndrome & -0.121 (0.185) & $^{}$\\
Betacoronavirus & -0.118 (0.223) & $^{}$\\
Acute Coronary Syndrome/epidemiology & -0.118 (0.239) & $^{}$\\
Treatment Failure & -0.118 (0.118) & $^{}$\\
Hospitalization/statistics \& numerical data & -0.116 (0.078) & $^{}$\\
Insulin/therapeutic use & -0.116 (0.173) & $^{}$\\
Anti-Bacterial Agents/adverse effects & -0.116 (0.177) & $^{}$\\
Severity of Illness Index & -0.115 (0.040) & $^{**}$\\
Renal Insufficiency, Chronic/epidemiology & -0.114 (0.156) & $^{}$\\
Walking & -0.114 (0.168) & $^{}$\\
Acute Disease & -0.113 (0.083) & $^{}$\\
Regression Analysis & -0.113 (0.097) & $^{}$\\
HIV Infections/epidemiology & -0.112 (0.127) & $^{}$\\
Heart Ventricles/physiopathology & -0.110 (0.237) & $^{}$\\
Respiration, Artificial/adverse effects & -0.109 (0.179) & $^{}$\\
Cardiovascular Diseases/etiology & -0.109 (0.153) & $^{}$\\
Birth Weight & -0.108 (0.132) & $^{}$\\
Echocardiography & -0.106 (0.100) & $^{}$\\
Europe/epidemiology & -0.106 (0.151) & $^{}$\\
Aging & -0.105 (0.194) & $^{}$\\
Atrial Fibrillation/surgery & -0.104 (0.173) & $^{}$\\
Crohn Disease/drug therapy & -0.104 (0.161) & $^{}$\\
Patient Discharge & -0.103 (0.099) & $^{}$\\
Sleep & -0.103 (0.140) & $^{}$\\
Linear Models & -0.100 (0.087) & $^{}$\\
Postoperative Complications/etiology & -0.100 (0.074) & $^{}$\\
Parity & -0.099 (0.191) & $^{}$\\
Analysis of Variance & -0.098 (0.135) & $^{}$\\
Lung Neoplasms/drug therapy & -0.097 (0.259) & $^{}$\\
Sepsis/epidemiology & -0.097 (0.178) & $^{}$\\
Ventricular Function, Left/physiology & -0.095 (0.203) & $^{}$\\
Ethnicity & -0.095 (0.167) & $^{}$\\
Kidney Transplantation/adverse effects & -0.094 (0.150) & $^{}$\\
Adolescent & -0.094 (0.033) & $^{**}$\\
Injury Severity Score & -0.093 (0.134) & $^{}$\\
Hemorrhage/epidemiology & -0.092 (0.181) & $^{}$\\
Retina/pathology & -0.091 (0.199) & $^{}$\\
Bone Density & -0.090 (0.171) & $^{}$\\
Out-of-Hospital Cardiac Arrest/mortality & -0.089 (0.188) & $^{}$\\
Exercise & -0.089 (0.101) & $^{}$\\
Cardiovascular Diseases/epidemiology & -0.088 (0.113) & $^{}$\\
Antineoplastic Agents/therapeutic use & -0.087 (0.132) & $^{}$\\
Body Mass Index & -0.087 (0.061) & $^{}$\\
Atrial Fibrillation/drug therapy & -0.087 (0.156) & $^{}$\\
Critical Illness/mortality & -0.086 (0.167) & $^{}$\\
Critical Care/methods & -0.085 (0.154) & $^{}$\\
Kidney Failure, Chronic/blood & -0.084 (0.249) & $^{}$\\
Cerebrovascular Circulation & -0.084 (0.186) & $^{}$\\
Activities of Daily Living & -0.082 (0.099) & $^{}$\\
Nerve Fibers/pathology & -0.080 (0.298) & $^{}$\\
Arthritis, Rheumatoid/drug therapy & -0.079 (0.152) & $^{}$\\
Depression/diagnosis & -0.078 (0.177) & $^{}$\\
Diabetes Mellitus/epidemiology & -0.077 (0.127) & $^{}$\\
Emergency Medical Services/statistics \& numerical data & -0.076 (0.190) & $^{}$\\
Percutaneous Coronary Intervention/mortality & -0.075 (0.175) & $^{}$\\
Survival Analysis & -0.074 (0.079) & $^{}$\\
Fibrinolytic Agents/therapeutic use & -0.074 (0.188) & $^{}$\\
Female & -0.074 (0.032) & $^{*}$\\
Health Surveys & -0.071 (0.185) & $^{}$\\
Age Factors & -0.070 (0.051) & $^{}$\\
Stroke/physiopathology & -0.070 (0.160) & $^{}$\\
Mental Health & -0.069 (0.136) & $^{}$\\
Genetic Predisposition to Disease & -0.069 (0.159) & $^{}$\\
Respiratory Function Tests & -0.068 (0.163) & $^{}$\\
Surveys and Questionnaires & -0.064 (0.041) & $^{}$\\
Postoperative Period & -0.062 (0.088) & $^{}$\\
Blood Pressure/physiology & -0.062 (0.126) & $^{}$\\
Exercise/physiology & -0.061 (0.144) & $^{}$\\
Prostatic Neoplasms/pathology & -0.061 (0.202) & $^{}$\\
Pregnancy Outcome & -0.060 (0.116) & $^{}$\\
Heart Failure/epidemiology & -0.060 (0.145) & $^{}$\\
Physicians & -0.060 (0.161) & $^{}$\\
Hypoglycemic Agents/administration \& dosage & -0.059 (0.171) & $^{}$\\
Pulmonary Disease, Chronic Obstructive/diagnosis & -0.059 (0.180) & $^{}$\\
Population Surveillance & -0.059 (0.199) & $^{}$\\
Odds Ratio & -0.059 (0.074) & $^{}$\\
Delivery of Health Care & -0.056 (0.154) & $^{}$\\
Stroke/epidemiology & -0.055 (0.119) & $^{}$\\
Socioeconomic Factors & -0.054 (0.085) & $^{}$\\
Comorbidity & -0.054 (0.058) & $^{}$\\
Kaplan-Meier Estimate & -0.053 (0.068) & $^{}$\\
Coronary Angiography & -0.053 (0.112) & $^{}$\\
Percutaneous Coronary Intervention/methods & -0.052 (0.165) & $^{}$\\
Overweight/epidemiology & -0.051 (0.211) & $^{}$\\
Social Support & -0.051 (0.184) & $^{}$\\
Renal Insufficiency, Chronic/physiopathology & -0.051 (0.184) & $^{}$\\
Anesthesia, General & -0.051 (0.165) & $^{}$\\
Heart Ventricles/diagnostic imaging & -0.051 (0.215) & $^{}$\\
Pregnancy & -0.050 (0.053) & $^{}$\\
Waist Circumference & -0.048 (0.201) & $^{}$\\
Propensity Score & -0.046 (0.075) & $^{}$\\
Wounds and Injuries/therapy & -0.046 (0.183) & $^{}$\\
Brain/diagnostic imaging & -0.045 (0.154) & $^{}$\\
Fibrosis & -0.045 (0.199) & $^{}$\\
Acute Kidney Injury/etiology & -0.044 (0.152) & $^{}$\\
Blood Flow Velocity & -0.043 (0.180) & $^{}$\\
Liver Cirrhosis/complications & -0.043 (0.159) & $^{}$\\
Metabolic Syndrome/epidemiology & -0.042 (0.206) & $^{}$\\
Health Behavior & -0.041 (0.178) & $^{}$\\
Infant & -0.041 (0.048) & $^{}$\\
Guideline Adherence/statistics \& numerical data & -0.040 (0.180) & $^{}$\\
Defibrillators, Implantable & -0.039 (0.179) & $^{}$\\
Disease-Free Survival & -0.039 (0.096) & $^{}$\\
Liver/pathology & -0.037 (0.187) & $^{}$\\
Heart Failure/etiology & -0.037 (0.222) & $^{}$\\
Heart Failure/mortality & -0.037 (0.139) & $^{}$\\
Neoplasms/complications & -0.037 (0.143) & $^{}$\\
Platelet Count & -0.036 (0.177) & $^{}$\\
APACHE & -0.036 (0.153) & $^{}$\\
Aged, 80 and over & -0.036 (0.027) & $^{}$\\
Intensive Care Units/organization \& administration & -0.035 (0.199) & $^{}$\\
Trauma Centers & -0.035 (0.162) & $^{}$\\
Aortic Valve Stenosis/surgery & -0.032 (0.208) & $^{}$\\
Reproducibility of Results & -0.032 (0.064) & $^{}$\\
Tomography, X-Ray Computed/methods & -0.031 (0.130) & $^{}$\\
Aged & -0.030 (0.024) & $^{}$\\
Pain Measurement/methods & -0.030 (0.159) & $^{}$\\
Acute Coronary Syndrome/mortality & -0.030 (0.211) & $^{}$\\
Cardiovascular Diseases/mortality & -0.029 (0.154) & $^{}$\\
Tumor Necrosis Factor-alpha/antagonists \& inhibitors & -0.029 (0.157) & $^{}$\\
Quality of Health Care & -0.027 (0.158) & $^{}$\\
Physician-Patient Relations & -0.026 (0.172) & $^{}$\\
Pregnancy Complications/epidemiology & -0.026 (0.172) & $^{}$\\
Psychiatric Status Rating Scales & -0.025 (0.147) & $^{}$\\
Brain Ischemia/diagnosis & -0.023 (0.224) & $^{}$\\
Primary Health Care & -0.023 (0.110) & $^{}$\\
Cesarean Section & -0.022 (0.151) & $^{}$\\
Mutation & -0.022 (0.121) & $^{}$\\
Acute Kidney Injury/epidemiology & -0.021 (0.161) & $^{}$\\
Adrenergic beta-Antagonists/therapeutic use & -0.021 (0.202) & $^{}$\\
Age Distribution & -0.019 (0.155) & $^{}$\\
Glycated Hemoglobin/metabolism & -0.019 (0.143) & $^{}$\\
Inflammatory Bowel Diseases/drug therapy & -0.017 (0.174) & $^{}$\\
Adalimumab/therapeutic use & -0.017 (0.201) & $^{}$\\
Malnutrition/epidemiology & -0.015 (0.207) & $^{}$\\
Administration, Inhalation & -0.015 (0.182) & $^{}$\\
Critical Illness/therapy & -0.014 (0.124) & $^{}$\\
Heart Failure/complications & -0.013 (0.156) & $^{}$\\
Health Status Disparities & -0.013 (0.195) & $^{}$\\
Male & -0.013 (0.030) & $^{}$\\
Lung/physiopathology & -0.012 (0.154) & $^{}$\\
Blood Vessel Prosthesis Implantation/adverse effects & -0.011 (0.196) & $^{}$\\
Patient Selection & -0.010 (0.121) & $^{}$\\
Hospitalization/economics & -0.010 (0.180) & $^{}$\\
Aortic Valve/physiopathology & -0.010 (0.336) & $^{}$\\
Retrospective Studies & -0.008 (0.021) & $^{}$\\
Polysomnography & -0.006 (0.164) & $^{}$\\
Diabetes Mellitus, Type 2/blood & -0.005 (0.131) & $^{}$\\
Nutritional Status & -0.005 (0.116) & $^{}$\\
Anxiety/etiology & -0.003 (0.213) & $^{}$\\
Adult & -0.003 (0.021) & $^{}$\\
Triglycerides/blood & -0.002 (0.186) & $^{}$\\
Infant, Newborn & -0.002 (0.048) & $^{}$\\
Colorectal Neoplasms/surgery & -0.002 (0.170) & $^{}$\\
Organ Dysfunction Scores & -0.001 (0.176) & $^{}$\\
Anxiety/psychology & -0.000 (0.169) & $^{}$\\
Diabetes Mellitus, Type 2/physiopathology & -0.000 (0.186) & $^{}$\\
Child, Preschool & 0.000 (0.051) & $^{}$\\
Vital Capacity & 0.002 (0.222) & $^{}$\\
Blood Transfusion & 0.003 (0.162) & $^{}$\\
Patient Admission/statistics \& numerical data & 0.003 (0.167) & $^{}$\\
Acute Coronary Syndrome/therapy & 0.003 (0.197) & $^{}$\\
Endovascular Procedures/adverse effects & 0.004 (0.170) & $^{}$\\
Risk Assessment & 0.005 (0.047) & $^{}$\\
Hemorrhage/etiology & 0.006 (0.166) & $^{}$\\
Neoplasm Staging & 0.006 (0.089) & $^{}$\\
Asthma/drug therapy & 0.008 (0.165) & $^{}$\\
Infliximab/therapeutic use & 0.009 (0.191) & $^{}$\\
Hospitalization/trends & 0.009 (0.161) & $^{}$\\
Exercise Test & 0.010 (0.148) & $^{}$\\
Antihypertensive Agents/therapeutic use & 0.011 (0.155) & $^{}$\\
Atrial Fibrillation/complications & 0.011 (0.147) & $^{}$\\
Anxiety/epidemiology & 0.012 (0.172) & $^{}$\\
Coronary Artery Disease/therapy & 0.014 (0.167) & $^{}$\\
Adrenal Cortex Hormones/therapeutic use & 0.015 (0.145) & $^{}$\\
COVID-19 Drug Treatment & 0.015 (0.167) & $^{}$\\
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use & 0.016 (0.138) & $^{}$\\
Hypoglycemic Agents/therapeutic use & 0.017 (0.132) & $^{}$\\
Emergency Service, Hospital & 0.018 (0.068) & $^{}$\\
Blood Glucose/metabolism & 0.019 (0.116) & $^{}$\\
Anticoagulants/administration \& dosage & 0.019 (0.155) & $^{}$\\
Pain & 0.022 (0.135) & $^{}$\\
Stroke/drug therapy & 0.023 (0.171) & $^{}$\\
Acute Coronary Syndrome/diagnosis & 0.023 (0.186) & $^{}$\\
Myocardial Infarction/therapy & 0.024 (0.172) & $^{}$\\
Emergencies & 0.025 (0.184) & $^{}$\\
Risk Assessment/methods & 0.027 (0.098) & $^{}$\\
Coronary Artery Disease/diagnosis & 0.027 (0.164) & $^{}$\\
Time Factors & 0.027 (0.032) & $^{}$\\
Middle Aged & 0.028 (0.025) & $^{}$\\
Neoplasms/therapy & 0.029 (0.160) & $^{}$\\
Asymptomatic Diseases & 0.029 (0.213) & $^{}$\\
Pilot Projects & 0.030 (0.062) & $^{}$\\
Analgesics, Opioid/therapeutic use & 0.032 (0.124) & $^{}$\\
Prospective Studies & 0.033 (0.020) & $^{}$\\
Blood Glucose/drug effects & 0.035 (0.206) & $^{}$\\
Renal Insufficiency, Chronic/mortality & 0.036 (0.227) & $^{}$\\
Cost of Illness & 0.036 (0.124) & $^{}$\\
Chronic Disease & 0.037 (0.077) & $^{}$\\
Coronary Artery Disease/surgery & 0.037 (0.155) & $^{}$\\
Endovascular Procedures/mortality & 0.038 (0.226) & $^{}$\\
Obesity/complications & 0.038 (0.110) & $^{}$\\
Catheter Ablation/adverse effects & 0.039 (0.185) & $^{}$\\
Retinal Ganglion Cells/pathology & 0.040 (0.293) & $^{}$\\
Colorectal Neoplasms/pathology & 0.041 (0.149) & $^{}$\\
Body Composition & 0.041 (0.156) & $^{}$\\
Coronary Artery Disease/complications & 0.042 (0.186) & $^{}$\\
Infant, Premature & 0.042 (0.103) & $^{}$\\
Cause of Death & 0.043 (0.106) & $^{}$\\
Kidney Transplantation & 0.044 (0.155) & $^{}$\\
ST Elevation Myocardial Infarction/therapy & 0.046 (0.210) & $^{}$\\
Diabetes Mellitus, Type 2/therapy & 0.050 (0.190) & $^{}$\\
Chemotherapy, Adjuvant & 0.050 (0.176) & $^{}$\\
Pain Measurement & 0.051 (0.089) & $^{}$\\
Heart Rate & 0.052 (0.130) & $^{}$\\
Survival Rate/trends & 0.053 (0.108) & $^{}$\\
Diagnosis, Differential & 0.053 (0.135) & $^{}$\\
Obesity, Morbid/surgery & 0.054 (0.144) & $^{}$\\
COVID-19/therapy & 0.056 (0.129) & $^{}$\\
Registries/statistics \& numerical data & 0.057 (0.170) & $^{}$\\
Breast Neoplasms/pathology & 0.058 (0.139) & $^{}$\\
Black or African American & 0.058 (0.225) & $^{}$\\
Renal Insufficiency, Chronic/complications & 0.060 (0.137) & $^{}$\\
Arthritis, Rheumatoid/diagnosis & 0.060 (0.190) & $^{}$\\
Contrast Media & 0.061 (0.187) & $^{}$\\
Neoplasms/drug therapy & 0.062 (0.145) & $^{}$\\
Renal Insufficiency, Chronic/therapy & 0.064 (0.173) & $^{}$\\
Genotype & 0.065 (0.109) & $^{}$\\
Sepsis/complications & 0.066 (0.179) & $^{}$\\
Academic Medical Centers & 0.074 (0.168) & $^{}$\\
Intensive Care Units/statistics \& numerical data & 0.074 (0.114) & $^{}$\\
Radiography & 0.074 (0.128) & $^{}$\\
Coronary Artery Disease/diagnostic imaging & 0.074 (0.145) & $^{}$\\
Mental Disorders/epidemiology & 0.076 (0.176) & $^{}$\\
Coronary Artery Disease/blood & 0.077 (0.198) & $^{}$\\
Myocardial Infarction/blood & 0.080 (0.234) & $^{}$\\
Smoking/epidemiology & 0.080 (0.152) & $^{}$\\
Seasons & 0.081 (0.139) & $^{}$\\
Renal Dialysis/adverse effects & 0.081 (0.148) & $^{}$\\
Cross Infection/epidemiology & 0.082 (0.153) & $^{}$\\
Atrial Fibrillation/physiopathology & 0.084 (0.162) & $^{}$\\
HIV Infections/virology & 0.087 (0.197) & $^{}$\\
Hospitals & 0.087 (0.079) & $^{}$\\
Renal Insufficiency, Chronic/diagnosis & 0.087 (0.181) & $^{}$\\
Child & 0.088 (0.038) & $^{*}$\\
Intraocular Pressure & 0.089 (0.145) & $^{}$\\
Intubation, Intratracheal & 0.092 (0.180) & $^{}$\\
Anti-Bacterial Agents/therapeutic use & 0.093 (0.072) & $^{}$\\
Postoperative Complications/mortality & 0.094 (0.134) & $^{}$\\
Young Adult & 0.094 (0.031) & $^{**}$\\
Diabetes Mellitus, Type 2/mortality & 0.096 (0.214) & $^{}$\\
Respiration, Artificial/methods & 0.097 (0.162) & $^{}$\\
Action Potentials & 0.098 (0.238) & $^{}$\\
Tertiary Care Centers & 0.098 (0.074) & $^{}$\\
Stroke/therapy & 0.099 (0.139) & $^{}$\\
Sensitivity and Specificity & 0.100 (0.073) & $^{}$\\
Follow-Up Studies & 0.101 (0.031) & $^{**}$\\
Intensive Care Units, Neonatal & 0.102 (0.142) & $^{}$\\
Postoperative Complications & 0.103 (0.110) & $^{}$\\
Bariatric Surgery & 0.105 (0.182) & $^{}$\\
Hemorrhage/chemically induced & 0.106 (0.145) & $^{}$\\
Practice Guidelines as Topic & 0.107 (0.111) & $^{}$\\
Glycated Hemoglobin/analysis & 0.109 (0.125) & $^{}$\\
Survival Rate & 0.109 (0.073) & $^{}$\\
Postoperative Complications/therapy & 0.110 (0.188) & $^{}$\\
Echocardiography, Doppler & 0.111 (0.196) & $^{}$\\
Colonoscopy & 0.112 (0.168) & $^{}$\\
Antineoplastic Combined Chemotherapy Protocols/therapeutic use & 0.112 (0.121) & $^{}$\\
Kidney Failure, Chronic/therapy & 0.112 (0.146) & $^{}$\\
Ventricular Dysfunction, Left/physiopathology & 0.112 (0.225) & $^{}$\\
Reoperation & 0.113 (0.122) & $^{}$\\
Laparoscopy & 0.115 (0.133) & $^{}$\\
Length of Stay/statistics \& numerical data & 0.117 (0.083) & $^{}$\\
Stroke Rehabilitation & 0.118 (0.191) & $^{}$\\
Graft Survival & 0.118 (0.160) & $^{}$\\
Rural Population & 0.119 (0.169) & $^{}$\\
Early Diagnosis & 0.121 (0.137) & $^{}$\\
Endovascular Procedures/instrumentation & 0.124 (0.215) & $^{}$\\
Coronary Angiography/methods & 0.124 (0.175) & $^{}$\\
Hypertension/physiopathology & 0.127 (0.175) & $^{}$\\
Delirium/epidemiology & 0.128 (0.229) & $^{}$\\
Atrial Fibrillation/diagnosis & 0.128 (0.139) & $^{}$\\
Statistics, Nonparametric & 0.129 (0.130) & $^{}$\\
Elective Surgical Procedures & 0.131 (0.154) & $^{}$\\
Obesity/diagnosis & 0.132 (0.211) & $^{}$\\
Drug-Related Side Effects and Adverse Reactions/epidemiology & 0.134 (0.165) & $^{}$\\
Patient Compliance & 0.134 (0.150) & $^{}$\\
Stroke/mortality & 0.134 (0.155) & $^{}$\\
COVID-19/epidemiology & 0.135 (0.076) & $^{}$\\
Ventricular Function, Left & 0.135 (0.140) & $^{}$\\
Neoplasm Recurrence, Local & 0.136 (0.166) & $^{}$\\
HIV Infections/drug therapy & 0.137 (0.132) & $^{}$\\
Europe & 0.138 (0.123) & $^{}$\\
Percutaneous Coronary Intervention/instrumentation & 0.139 (0.203) & $^{}$\\
Length of Stay & 0.141 (0.064) & $^{*}$\\
Chi-Square Distribution & 0.145 (0.095) & $^{}$\\
Anti-Bacterial Agents/administration \& dosage & 0.145 (0.134) & $^{}$\\
Palliative Care & 0.147 (0.169) & $^{}$\\
Recurrence & 0.150 (0.063) & $^{*}$\\
Range of Motion, Articular & 0.150 (0.155) & $^{}$\\
Diabetes Mellitus, Type 2/diagnosis & 0.153 (0.145) & $^{}$\\
Breast Neoplasms/drug therapy & 0.153 (0.146) & $^{}$\\
Asian People & 0.155 (0.150) & $^{}$\\
Diet & 0.157 (0.144) & $^{}$\\
COVID-19 & 0.161 (0.083) & $^{}$\\
Heart Failure/therapy & 0.163 (0.132) & $^{}$\\
Coronary Artery Disease/mortality & 0.164 (0.162) & $^{}$\\
Lumbar Vertebrae/surgery & 0.165 (0.155) & $^{}$\\
Educational Status & 0.167 (0.143) & $^{}$\\
Heart Failure/drug therapy & 0.167 (0.170) & $^{}$\\
Respiratory Distress Syndrome/therapy & 0.171 (0.166) & $^{}$\\
CD4 Lymphocyte Count & 0.172 (0.166) & $^{}$\\
Aortic Valve/diagnostic imaging & 0.172 (0.276) & $^{}$\\
Cause of Death/trends & 0.173 (0.224) & $^{}$\\
Aortic Valve Stenosis/mortality & 0.174 (0.236) & $^{}$\\
Administration, Oral & 0.177 (0.100) & $^{}$\\
Humans & 0.179 (0.196) & $^{}$\\
Health Personnel & 0.182 (0.144) & $^{}$\\
Platelet Aggregation Inhibitors/adverse effects & 0.182 (0.188) & $^{}$\\
Pandemics & 0.185 (0.079) & $^{*}$\\
Hemodynamics & 0.187 (0.108) & $^{}$\\
Communicable Disease Control & 0.188 (0.163) & $^{}$\\
Breast Neoplasms/surgery & 0.190 (0.160) & $^{}$\\
Intubation, Intratracheal/methods & 0.191 (0.165) & $^{}$\\
Hip Fractures/surgery & 0.191 (0.159) & $^{}$\\
Referral and Consultation & 0.195 (0.109) & $^{}$\\
Surgical Wound Infection/epidemiology & 0.196 (0.171) & $^{}$\\
Observer Variation & 0.196 (0.163) & $^{}$\\
Heart Arrest/therapy & 0.197 (0.183) & $^{}$\\
Anticonvulsants/therapeutic use & 0.197 (0.176) & $^{}$\\
Hypertension/epidemiology & 0.197 (0.123) & $^{}$\\
Hospitals, University & 0.198 (0.114) & $^{}$\\
Patient Acceptance of Health Care/statistics \& numerical data & 0.199 (0.155) & $^{}$\\
Immunosuppressive Agents/therapeutic use & 0.200 (0.116) & $^{}$\\
Oxygen/blood & 0.201 (0.145) & $^{}$\\
Coronavirus Infections/epidemiology & 0.204 (0.470) & $^{}$\\
Hemodynamics/physiology & 0.205 (0.181) & $^{}$\\
Outpatients & 0.208 (0.134) & $^{}$\\
Cardiac Catheterization/adverse effects & 0.208 (0.189) & $^{}$\\
Healthy Volunteers & 0.210 (0.117) & $^{}$\\
Physical Therapy Modalities & 0.213 (0.160) & $^{}$\\
Pulse Wave Analysis & 0.214 (0.225) & $^{}$\\
Body Weight & 0.215 (0.124) & $^{}$\\
Visual Acuity & 0.216 (0.087) & $^{*}$\\
Endovascular Procedures/methods & 0.226 (0.174) & $^{}$\\
Antiviral Agents/therapeutic use & 0.230 (0.122) & $^{}$\\
Anti-HIV Agents/therapeutic use & 0.231 (0.169) & $^{}$\\
Energy Intake & 0.231 (0.164) & $^{}$\\
Acute Kidney Injury/therapy & 0.234 (0.167) & $^{}$\\
Decision Making & 0.235 (0.149) & $^{}$\\
Diabetes Mellitus, Type 2/drug therapy & 0.241 (0.122) & $^{*}$\\
Myocardial Infarction/diagnosis & 0.241 (0.164) & $^{}$\\
Quality of Life/psychology & 0.242 (0.117) & $^{*}$\\
Breast Feeding & 0.247 (0.177) & $^{}$\\
Pain/etiology & 0.249 (0.144) & $^{}$\\
Acute Kidney Injury/blood & 0.252 (0.229) & $^{}$\\
Protective Factors & 0.252 (0.167) & $^{}$\\
Area Under Curve & 0.253 (0.126) & $^{*}$\\
Hypertension/drug therapy & 0.254 (0.162) & $^{}$\\
Clinical Decision-Making & 0.255 (0.136) & $^{}$\\
Diabetes Mellitus/diagnosis & 0.255 (0.194) & $^{}$\\
Smoking/adverse effects & 0.255 (0.155) & $^{}$\\
Hemoglobins/analysis & 0.256 (0.168) & $^{}$\\
Drug Administration Schedule & 0.256 (0.095) & $^{**}$\\
Drug Therapy, Combination & 0.257 (0.076) & $^{***}$\\
Visual Acuity/physiology & 0.263 (0.122) & $^{*}$\\
Neoplasm Recurrence, Local/pathology & 0.263 (0.154) & $^{}$\\
Immunosuppressive Agents/adverse effects & 0.264 (0.163) & $^{}$\\
Hospitals, Teaching & 0.266 (0.143) & $^{}$\\
Triage & 0.270 (0.162) & $^{}$\\
Preoperative Care/methods & 0.270 (0.174) & $^{}$\\
Attitude of Health Personnel & 0.271 (0.139) & $^{}$\\
Outcome Assessment, Health Care & 0.275 (0.083) & $^{***}$\\
Combined Modality Therapy & 0.277 (0.117) & $^{*}$\\
Hypoglycemic Agents/adverse effects & 0.279 (0.167) & $^{}$\\
Respiratory Insufficiency/therapy & 0.280 (0.154) & $^{}$\\
Pulmonary Disease, Chronic Obstructive/drug therapy & 0.280 (0.205) & $^{}$\\
Carcinoma, Non-Small-Cell Lung/drug therapy & 0.282 (0.298) & $^{}$\\
Recovery of Function & 0.285 (0.082) & $^{***}$\\
Infusions, Intravenous & 0.287 (0.147) & $^{}$\\
Health Knowledge, Attitudes, Practice & 0.287 (0.111) & $^{**}$\\
Prosthesis Design & 0.287 (0.108) & $^{**}$\\
Laparoscopy/methods & 0.292 (0.126) & $^{*}$\\
Stroke/prevention \& control & 0.297 (0.160) & $^{}$\\
Antineoplastic Agents/adverse effects & 0.297 (0.152) & $^{}$\\
Brain Ischemia/complications & 0.297 (0.206) & $^{}$\\
Electronic Health Records & 0.300 (0.129) & $^{*}$\\
Lung Neoplasms/pathology & 0.301 (0.214) & $^{}$\\
Dose-Response Relationship, Drug & 0.304 (0.096) & $^{**}$\\
Interleukin-6/blood & 0.307 (0.185) & $^{}$\\
Communication & 0.308 (0.136) & $^{*}$\\
Time-to-Treatment & 0.310 (0.118) & $^{**}$\\
Tertiary Care Centers/statistics \& numerical data & 0.310 (0.170) & $^{}$\\
Heart Valve Prosthesis & 0.315 (0.185) & $^{}$\\
Lumbar Vertebrae/diagnostic imaging & 0.315 (0.175) & $^{}$\\
Operative Time & 0.317 (0.118) & $^{**}$\\
Cholesterol, LDL/blood & 0.317 (0.184) & $^{}$\\
Vitamin D/analogs \& derivatives & 0.322 (0.279) & $^{}$\\
Internship and Residency & 0.323 (0.156) & $^{*}$\\
Antibodies, Monoclonal, Humanized/therapeutic use & 0.330 (0.130) & $^{*}$\\
Natriuretic Peptide, Brain/blood & 0.331 (0.219) & $^{}$\\
Vascular Patency & 0.342 (0.163) & $^{*}$\\
Coronary Vessels/diagnostic imaging & 0.342 (0.162) & $^{*}$\\
Hemoglobins/metabolism & 0.342 (0.176) & $^{}$\\
Progression-Free Survival & 0.347 (0.144) & $^{*}$\\
Animals & 0.351 (0.095) & $^{***}$\\
Analgesics, Opioid/administration \& dosage & 0.352 (0.165) & $^{*}$\\
Stents & 0.355 (0.112) & $^{**}$\\
Outcome and Process Assessment, Health Care & 0.356 (0.162) & $^{*}$\\
Remission Induction & 0.360 (0.115) & $^{**}$\\
Obesity/physiopathology & 0.361 (0.178) & $^{*}$\\
Cardiac Surgical Procedures/methods & 0.361 (0.181) & $^{*}$\\
Quality of Life & 0.362 (0.041) & $^{***}$\\
Weight Loss & 0.370 (0.124) & $^{**}$\\
Pain Management/methods & 0.373 (0.150) & $^{*}$\\
Decision Support Techniques & 0.381 (0.143) & $^{**}$\\
Glucocorticoids/therapeutic use & 0.382 (0.148) & $^{**}$\\
Forced Expiratory Volume & 0.389 (0.173) & $^{*}$\\
Pain, Postoperative/drug therapy & 0.392 (0.155) & $^{*}$\\
Vaccination & 0.394 (0.144) & $^{**}$\\
Administration, Intravenous & 0.399 (0.140) & $^{**}$\\
Patient Satisfaction & 0.401 (0.090) & $^{***}$\\
Kidney/physiopathology & 0.402 (0.152) & $^{**}$\\
Point-of-Care Systems & 0.403 (0.169) & $^{*}$\\
Anti-Bacterial Agents/pharmacology & 0.411 (0.164) & $^{*}$\\
Emergency Service, Hospital/organization \& administration & 0.413 (0.154) & $^{**}$\\
Disease Management & 0.419 (0.144) & $^{**}$\\
Postoperative Complications/surgery & 0.437 (0.169) & $^{**}$\\
Life Style & 0.439 (0.141) & $^{**}$\\
Coronary Artery Bypass/mortality & 0.440 (0.245) & $^{}$\\
Antineoplastic Combined Chemotherapy Protocols/adverse effects & 0.443 (0.160) & $^{**}$\\
Guideline Adherence & 0.444 (0.144) & $^{**}$\\
Dietary Supplements & 0.444 (0.170) & $^{**}$\\
Cardiovascular Diseases/blood & 0.462 (0.180) & $^{*}$\\
Clinical Competence & 0.471 (0.111) & $^{***}$\\
Patient Safety & 0.475 (0.132) & $^{***}$\\
Intraocular Pressure/physiology & 0.475 (0.163) & $^{**}$\\
Postoperative Complications/prevention \& control & 0.483 (0.119) & $^{***}$\\
Blood Pressure/drug effects & 0.486 (0.173) & $^{**}$\\
Catheter Ablation/methods & 0.489 (0.181) & $^{**}$\\
Diabetes Mellitus, Type 1/drug therapy & 0.489 (0.187) & $^{**}$\\
Cardiovascular Diseases/prevention \& control & 0.491 (0.160) & $^{**}$\\
Treatment Outcome & 0.495 (0.024) & $^{***}$\\
Lipids/blood & 0.501 (0.167) & $^{**}$\\
Colitis, Ulcerative/drug therapy & 0.508 (0.173) & $^{**}$\\
Pulmonary Disease, Chronic Obstructive/therapy & 0.542 (0.195) & $^{**}$\\
Inflammation Mediators/blood & 0.557 (0.210) & $^{**}$\\
COVID-19/prevention \& control & 0.580 (0.111) & $^{***}$\\
Algorithms & 0.605 (0.106) & $^{***}$\\
Intravitreal Injections & 0.607 (0.147) & $^{***}$\\
Antibodies, Monoclonal/therapeutic use & 0.634 (0.170) & $^{***}$\\
Feasibility Studies & 0.654 (0.084) & $^{***}$\\
Hepatitis C, Chronic/drug therapy & 0.679 (0.173) & $^{***}$\\
Equipment Design & 0.682 (0.113) & $^{***}$\\
Ultrasonography, Interventional & 0.777 (0.161) & $^{***}$\\
Quality Improvement & 0.946 (0.126) & $^{***}$\\
Drug Combinations & 0.962 (0.122) & $^{***}$\\
Cost-Benefit Analysis & 1.019 (0.119) & $^{***}$\\
Program Evaluation & 1.312 (0.162) & $^{***}$\\
\end{longtable} \pagebreak
